GlassScriptPhysician profile
Jesus Roberto Ortiz
NPI 1821245473
$2,185.91
in general payments reported to CMS, 2019-2025
10 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $19.74 · 2021: $510 · 2022: $291 · 2023: $91.01 · 2024: $137 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $510.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $427.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $346.92 | 2019-2021 | |
| Lilly USA, LLC | $297.88 | 2023-2025 | Kisunla, Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $136.78 | 2024 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2025 | Iqirvo |
| Amgen INC. | $125.00 | 2021 | |
| Intercept Pharmaceuticals, INC. | $100.26 | 2019 | |
| Amarin Pharma, INC. | $97.13 | 2019 | |
| Emd Serono, INC. | $19.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.